Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 56


Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Sharma S, Babiker AG, Emery S, Gordin FM, Lundgren JD, Neaton JN, Bakowska E, Schechter M, Wiselka MJ, Wolff MJ; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:30-6. doi: 10.1111/hiv.12231.


Risk assessment for healthcare workers after a sentinel case of rabies and review of the literature.

Kan VL, Joyce P, Benator D, Agnes K, Gill J, Irmler M, Clark A, Giannakos G, Gabourel A, Gordin FM.

Clin Infect Dis. 2015 Feb 1;60(3):341-8. doi: 10.1093/cid/ciu850. Epub 2014 Oct 28. Review.


When to start antiretroviral therapy: the need for an evidence base during early HIV infection.

Lundgren JD, Babiker AG, Gordin FM, Borges ÁH, Neaton JD.

BMC Med. 2013 Jun 14;11:148. doi: 10.1186/1741-7015-11-148.


Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.


Progress realized: trends in HIV-1 viral load and CD4 cell count in a tertiary-care center from 1999 through 2011.

Gale HB, Rodriguez MD, Hoffman HJ, Benator DA, Gordin FM, Labriola AM, Kan VL.

PLoS One. 2013;8(2):e56845. doi: 10.1371/journal.pone.0056845. Epub 2013 Feb 20.


Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression?

Gale HB, Gitterman SR, Hoffman HJ, Gordin FM, Benator DA, Labriola AM, Kan VL.

Clin Infect Dis. 2013 May;56(9):1340-3. doi: 10.1093/cid/cit004. Epub 2013 Jan 11.


Current approaches to tuberculosis in the United States.

Gordin FM, Masur H.

JAMA. 2012 Jul 18;308(3):283-9. doi: 10.1001/jama.2012.7505.


Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, Lundgren JD, Neaton JD, Pett SL, Phillips A, Touloumi G, Vjechaj MJ; INSIGHT START Study Group.

Clin Trials. 2013;10(1 Suppl):S5-S36. doi: 10.1177/1740774512440342. Epub 2012 Apr 30.


Evaluating a decade of exposures to blood and body fluids in an inner-city teaching hospital.

Treakle AM, Schultz M, Giannakos GP, Joyce PC, Gordin FM.

Infect Control Hosp Epidemiol. 2011 Sep;32(9):903-7. doi: 10.1086/661281.


USA300 methicillin-resistant Staphylococcus aureus bacteremia and the risk of severe sepsis: is USA300 methicillin-resistant Staphylococcus aureus associated with more severe infections?

Kreisel KM, Stine OC, Johnson JK, Perencevich EN, Shardell MD, Lesse AJ, Gordin FM, Climo MW, Roghmann MC.

Diagn Microbiol Infect Dis. 2011 Jul;70(3):285-90. doi: 10.1016/j.diagmicrobio.2011.03.010. Epub 2011 May 10.


Illicit drug use and risk for USA300 methicillin-resistant Staphylococcus aureus infections with bacteremia.

Kreisel KM, Johnson JK, Stine OC, Shardell MD, Perencevich EN, Lesse AJ, Gordin FM, Climo MW, Roghmann MC.

Emerg Infect Dis. 2010 Sep;16(9):1419-27. doi: 10.3201/eid1609.091802.


Inside-out: the changing epidemiology of methicillin-resistant Staphylococcus aureus.

Kennedy LA, Gill JA, Schultz ME, Irmler M, Gordin FM.

Infect Control Hosp Epidemiol. 2010 Sep;31(9):983-5. doi: 10.1086/655837. No abstract available.


Assessing targeted screening and low rates of HIV testing.

Kennedy LA, Gordin FM, Kan VL.

Am J Public Health. 2010 Sep;100(9):1765-8. doi: 10.2105/AJPH.2009.182790. Epub 2010 Jul 15.


Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.

Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA; INSIGHT ESPRIT & SILCAAT study groups.

AIDS. 2010 Jul 31;24(12):1877-86. doi: 10.1097/QAD.0b013e32833b1b26.


Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.

Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, Rodriguez-Barradas MC, Wolff MJ, Easterbrook PJ, Clezy K, Slater LN.

Am J Respir Crit Care Med. 2008 Sep 15;178(6):630-6. doi: 10.1164/rccm.200804-617OC. Epub 2008 Jul 10.


A cluster of hemodialysis-related bacteremia linked to artificial fingernails.

Gordin FM, Schultz ME, Huber R, Zubairi S, Stock F, Kariyil J.

Infect Control Hosp Epidemiol. 2007 Jun;28(6):743-4. Epub 2007 Apr 19.


An official ATS statement: hepatotoxicity of antituberculosis therapy.

Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee.

Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. Review.


Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub.

Gordin FM, Schultz ME, Huber RA, Gill JA.

Infect Control Hosp Epidemiol. 2005 Jul;26(7):650-3.


Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ; Terry Beirn Community Programs for Clinical Research on AIDS; Adult AIDS Clinical Trials Group; Centers for Disease Control and Prevention.

Clin Infect Dis. 2004 Aug 15;39(4):561-5. Epub 2004 Jul 30.


Rifapentine for the treatment of tuberculosis: is it all it can be?

Gordin FM.

Am J Respir Crit Care Med. 2004 Jun 1;169(11):1176-7. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk